Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Published

Journal Article (Review)

With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

Full Text

Duke Authors

Cited Authors

  • Heimberger, AB; Sampson, JH

Published Date

  • January 2011

Published In

Volume / Issue

  • 13 / 1

Start / End Page

  • 3 - 13

PubMed ID

  • 21149252

Pubmed Central ID

  • 21149252

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/noq169

Language

  • eng

Conference Location

  • England